Company profile
60 Degrees Pharmaceuticals, Inc.
NASDAQ: SXTP · Healthcare · Biotechnology
#872 of 1,418 Healthcare companies by revenuetop-quartile growth
EA Score
34DFH 35DQ 19GM 73SS 16
v0.1 · 65/100 weight · provisional
↑ 3-yr revenue growth, revenue growth (YoY) · ↓ listing tenure, workforce scale
Methodology →Revenue TTM
$1.1M
Rev growth YoY (TTM)
+68.0%
Net income (FY)
-$7.4M
Employees
3
as of 2026-08-25
Market cap
$871.1k
as of 2026-08-25
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$1.0M$1.0M2025
Net income-$7.4M-$7.4M2025
Operating income-$7.8M-$7.8M2025
Total assets$5.4M$5.4M2025
Liabilities$2.0M$2.0M2025
Equity$3.5M$3.5M2025
Revenue trend
FY2023 – FY2025 · USD
FY23
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is 60 Degrees Pharmaceuticals, Inc.’s revenue?
60 Degrees Pharmaceuticals, Inc. booked $1.0M in FY2025 revenue, growing 65% year over year — faster than most Healthcare companies we track, at a -732.5% net margin.
Peers · Healthcare
Dare Bioscience, Inc.36DSintx Technologies, Inc.35DEhouse Global, Inc.——Shattuck Labs, Inc.49DRavenQuest BioMed Inc.——The CannaBusiness Group, Inc.——Neighbors
District of Columbia →Key facts
CEOGeoffrey Stuart Dow
SectorHealthcare
IndustryBiotechnology
HeadquartersWashington, DC
ExchangeNASDAQ: SXTP
Employees3
IPO date2023-07-12
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.